Navigation Links
Adalimumab is a promising therapy for children with Crohn's disease
Date:8/6/2012

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

Steroids are commonly used in Crohn's disease, but can stunt growth and delay puberty. Incidence of this disease, which causes intestinal inflammation, is on the rise in children.

This study is the largest double-blind study of an anti-TNF agent in children with Crohn's disease. It found that more than 80 percent of children with moderate to severe Crohn's disease responded to adalimumab within a month (response was defined as a decrease in Pediatric Crohn's Disease Activity Index ≥ 15 points from baseline). By six months, approximately 34 percent of patients were in clinical remission, and after a year, 28.4 percent were in remission.

The promising results of treatment with adalimumab are extremely encouraging, especially in this clinically challenging population resistant to conventional therapy. The goal of treatment is not only to induce and maintain clinical remission, but also to restore and preserve normal growth and pubertal development in these children.

Researchers studied 192 patients, ages 6 to 17 years, across 45 sites in Canada, Europe and the U.S. between April 2007 and May 2010. Depending on their body weight, patients were assigned to either a high-dose group, which received 40 mg of adalimumab every other week or 20 mg of adalimumab every other week. Patients assigned to a low-dose group either received 20 mg of adalimumab every other week or 10 mg of adalimumab every other week, again depending on their body weight. More children that received high than low dose were in remission at week 26, but the difference between dose groups was not statistically significant.


'/>"/>

Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Page: 1

Related medicine news :

1. Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
2. New study identifies promising, achievable solutions to Nigerias childhood mortality crisis
3. Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique
4. Stem Cell Study Shows Promising Results Against Heart Failure
5. Researchers make promising discovery in pursuit of effective lymphoma treatments
6. Diabetes drug could be a promising therapy for traumatic brain injury
7. Leukemia inhibitory factor may be a promising target against pancreatic cancer
8. Zebrafish reveal promising mechanism for healing spinal cord injury
9. Research identifies a promising new therapeutic target for aggressive breast cancer
10. Spice ingredient in curry emerges as promising basis for an Alzheimers disease medicine
11. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... The ... facelift . Dr. Talei has come up with a proprietary technique that he ... and lifts tissues that have dropped. For all ages, patients can expect to look ...
(Date:6/23/2017)... ... 2017 , ... 21 Middle East and South Asia Leaders Selected as Eisenhower ... business and civil society in 11 countries across the Middle East and South Asia ... transformative exchange of knowledge and ideas with the leading minds in their fields. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... planning, and related services to families and business owners in and around Lackawanna ... to benefit senior citizens in the area. , Meals on Wheels of NEPA ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & ... to families and business owners in North Central West Virginia, is embarking on ... to differently abled residents in the region. , The Stepping Stones organization offers ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading ... announced new findings demonstrating positive biochemical outcomes related to ... One™. The data will be presented at the ERA-EDTA ... Madrid, Spain . The research ... Dialysis Network in Europe ...
(Date:5/30/2017)... Holdings, Inc. (NYSE: HRC), will present at the Goldman Sachs ... 13, 2017, in Rancho Palos Verdes, California ... officer, is scheduled to present at 3:20 p.m. Pacific Time. ... http://ir.hill-rom.com/events.cfm . A recorded replay will be available one ... 2017. About Hill-Rom ...
(Date:5/26/2017)...  Endo International plc (NASDAQ: ENDP ) announced ... represent the Company in a fireside chat at Goldman Sachs, ... 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ET. ... Rancho Palos Verdes, CA. A ... available on the Company,s website at http://www.endo.com/investors/overview . Participants ...
Breaking Medicine Technology: